Valois Acquires New Inhaler
Valois Pharmaceutical Division (Marly-le-Roi, France) has acquired the rights to a dry powder inhaler from Quadrant Technologies Ltd. With this acquisition, the company has expanded its pulmonary franchise.
The device is a multidose inhaler based on a blister-type powder storage system. This system provides advanced moisture protection for the drug and high fine-particle fraction performance. According to Olivier Fourment, president of Valois, the technology complements the firmï¿½s metering valves used for pressurized metered dose inhalers. ï¿½It will allow us to strengthen our leading position in pulmonary drug delivery devices and offer pharmaceutical and biotechnology companies a portfolio of technologies to meet their pulmonary drug delivery needs,ï¿½ he said.
Valois has also secured the services of Quadrant Drug Delivery for the development of dry powder formulations suitable for the inhaler.